Abstract. A 47 year old woman examined for hypertension (200/100 mmHg) was normokalaemic, and had low plasma renin activity (PRA) (0.1 ng/ml \ m=. \ h) and normal aldosterone levels in both plasma (7\p=n-\13ng/dl) and urine (4.7\p=n-\7.4\g=m\g/day).Computed tomography (CT) and scintiscan indicated an adenoma on the right adrenal gland, which was then removed. The histology of the adenoma and analysis of the aldosterone content were compatible with the criteria for an aldosterone-producing adenoma. Three months after surgery, her hypertension had improved, serum potassium levels had increased slightly, and PRA had normalized. This was an unusual form of primary aldosteronism which showed normal levels of aldosterone in both blood and urine.
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Primary aldosteronism is usually recognized by hypertension, hypokalaemia, suppressed plasma renin activity (PRA) , and hyperaldosteronism (Conn 1955) . Variant forms have been reported however, e.g., normokalaemic (Conn et al. 1965; Bravo et al. 1983 ) and normotensive (Brooks et (Scheie 1953) : HI and So). There were no findings suggesting cardiomegaly either on chest X-ray (cardiothoracic ratio: 45%) or electrocardiography. Her serum potassium levels (3.4 and 3.6 mEq/1) were in the low normal range (normal: 3.4-4.5). Urinary excretion of 17-hydroxycorticosteroids (5.3 mg/day) and 17-ketosteroids (7.4 mg/day) was normal. PRA was suppressed: 0.1 mg/ml · h. PAC was normal: 7.0 ng/dl at 08.00 h and 3.0 ng/dl at 20.00 h. Urinary aldosterone excretion (UAE) was also normal : 7.4 µg/day (normal : less than 10). After 3 days on a higher sodium diet (240 mEq/day), hormonal data showed no significant change, viz, PRA, (Nitta et al. 1976 ) was performed after dexamethasone administration (3 mg/ day for 5 days prior to NCL-6-[131I]injection, followed by 2 mg/day for 7 days). Adrenal uptake of the radioimaging agent was relatively higher at the right (0.12% of the injected dose) than at the left gland (0.04%). To (1967) reported. These findings indicate this to be an aldosterone-producing adenoma. The unique fea¬ ture, however, is that our patient lacked some of the clinical features of primary aldosteronism which could be caused by an aldosterone-produc¬ ing adenoma, viz, hyperaldosteronism and hypokalaemia. The serum potassium level in primary aldosteronims is dependent on sodium intake (Bravo et al. 1983) , and normokalaemic primary aldosteronism is actually not very rare (Conn et (Nadler et al. 1984) . To eliminate such a possibility, we stopped the medication on the days blood samples were taken for hormonal evaluation. Thus, the period between blood sampling and drug admi¬ nistration (the last evening) was more than 12 h, which is much beyond the half-life of labetalol (less than 6 h) (Martin et al. 1978) and of nicardipine HCI (about 1 h) (Higuchi & Shiobara 1980) . Fur¬ thermore, we observed that 3 days of off therapy did not cause any change in aldosterone levels in either blood or urine. Thus, it seems unlikely that such a drug effect was acting to lower aldosterone levels in blood and urine in this case. Gross et al. (1983) reported that the adrenal uptake of the imaging agent (NCL-9) after dexa¬ methasone treatment correlates significantly with urinary aldosterone excretion in patients with primary aldosteronism, suggesting that the uptake reflects the functional activity of an aldosteroneproducing adenoma. Their conclusion was sup¬ ported in our adrenal scintigraphy procedure: urinary aldosterone excretion correlated signifi¬ cantly with adrenal uptake on the adenoma side (r = 0.925, < 0.01) in 6 cases which were all surgically confirmed to have aldosterone-producing adenomas (unpublished data). In the case de¬ scribed in this paper, adrenal uptake on the ade¬ noma side was higher than that on the opposite side (0.12 vs 0.04%), but was the lowest of the 6 cases we have studied (n = 6, ranging from 0.13 to 0.86%). All results indicate that this aldosteroneproducing adenoma had relatively weak activity and that it secreted comparatively less aldosterone, but sufficient to suppress renin secretion and to cause hypertension even though aldosterone levels remained within the normal range. The contribu¬ tion of the adenoma to hypertension and suppres¬ sion of renin is shown by the patient's improvement after adrenalectomy.
This case demonstrates that, on rare occasions, primary aldosteronism can occur even without an obvious increase in aldosterone levels in the blood or urine and that physicians examining patients with low-renin hyertension may also need to check for primary aldosteronism.
